{"id":59381,"date":"2026-06-04T22:35:18","date_gmt":"2026-06-04T13:35:18","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4597\/"},"modified":"2026-08-23T13:56:03","modified_gmt":"2026-08-23T04:56:03","slug":"company-4597","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4597\/","title":{"rendered":"SOLASIA PHARMA K K"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4597","DATE":"2026-01-09","longName":"Solasia Pharma K.K.","company_name_ja":"","fullTimeEmployees":22,"address":"","phone":"","website":"https:\/\/www.solasia.co.jp","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":29,"financialCurrency":"","marketCap":7415,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-3.3300000000000001,"epsForward":0,"bookValue":0,"totalRevenue":429000000,"OperatingIncome":-860000000,"operatingMargins":-200.47,"NetIncome":-876000000,"profitMargins":-204.19999999999999,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-54.07,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:58:17.094388\", \"ticker\": \"4597\", \"ticker_full\": \"4597.T\", \"company_name\": \"SOLASIA PHARMA K K\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 28.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 13.95, \"institution_pct\": 0.49, \"major_holders\": [{\"label\": \"\", \"value\": 13.95}, {\"label\": \"\", \"value\": 0.49}, {\"label\": \"\", \"value\": 0.57}, {\"label\": \"\", \"value\": 5.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis\/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:04:46.637711\", \"ticker\": \"4597\", \"ticker_full\": \"4597.T\", \"company_name\": \"SOLASIA PHARMA K K\", \"company_info\": {\"name_en\": \"SOLASIA PHARMA K K\", \"long_name\": \"Solasia Pharma K.K.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.solasia.co.jp\", \"employees\": 22, \"country\": \"Japan\", \"city\": \"Minato\", \"address\": \"Sumitomo Fudosan Shiba-Koen Tower\", \"description\": \"Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis\/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 33.8, \"deviation\": -5.33, \"trend\": \"down\"}, \"ma_25\": {\"ma_value\": 29.88, \"deviation\": 7.1, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 27.07, \"deviation\": 18.23, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 30.06, \"deviation\": 6.45, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 429000000.0, \"revenue_fmt\": \"\u00a54\u5104\", \"gross_profit\": 207000000.0, \"gross_profit_fmt\": \"\u00a52\u5104\", \"operating_income\": -860000000.0, \"operating_income_fmt\": \"-\u00a59\u5104\", \"ebit\": -862000000.0, \"ebit_fmt\": \"-\u00a59\u5104\", \"net_income\": -876000000.0, \"net_income_fmt\": \"-\u00a59\u5104\", \"eps\": -3.33, \"operating_margin\": -200.47, \"total_assets\": 2078000000.0, \"total_assets_fmt\": \"\u00a521\u5104\", \"total_equity\": 1620000000.0, \"total_equity_fmt\": \"\u00a516\u5104\", \"total_debt\": 16000000.0, \"total_debt_fmt\": \"\u00a516.0M\", \"total_cash\": 1378000000.0, \"total_cash_fmt\": \"\u00a514\u5104\", \"equity_ratio\": 77.96, \"de_ratio\": 0.01, \"current_ratio\": 4.54, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": -204.2, \"roe\": -54.07, \"roa\": -42.16}, {\"year\": 2024, \"revenue\": 316000000.0, \"revenue_fmt\": \"\u00a53\u5104\", \"gross_profit\": 185000000.0, \"gross_profit_fmt\": \"\u00a52\u5104\", \"operating_income\": -1950000000.0, \"operating_income_fmt\": \"-\u00a520\u5104\", \"ebit\": -1956000000.0, \"ebit_fmt\": \"-\u00a520\u5104\", \"net_income\": -1941000000.0, \"net_income_fmt\": \"-\u00a519\u5104\", \"eps\": -8.9, \"operating_margin\": -617.09, \"total_assets\": 1356000000.0, \"total_assets_fmt\": \"\u00a514\u5104\", \"total_equity\": 1035000000.0, \"total_equity_fmt\": \"\u00a510\u5104\", \"total_debt\": 12000000.0, \"total_debt_fmt\": \"\u00a512.0M\", \"total_cash\": 875000000.0, \"total_cash_fmt\": \"\u00a59\u5104\", \"equity_ratio\": 76.33, \"de_ratio\": 0.01, \"current_ratio\": 4.44, \"operating_cf\": -1033000000.0, \"operating_cf_fmt\": \"-\u00a510\u5104\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 1180000000.0, \"financing_cf_fmt\": \"\u00a512\u5104\", \"free_cf\": -1034000000.0, \"free_cf_fmt\": \"-\u00a510\u5104\", \"net_margin\": -614.24, \"roe\": -187.54, \"roa\": -143.14}, {\"year\": 2023, \"revenue\": 617000000.0, \"revenue_fmt\": \"\u00a56\u5104\", \"gross_profit\": 337000000.0, \"gross_profit_fmt\": \"\u00a53\u5104\", \"operating_income\": -1139000000.0, \"operating_income_fmt\": \"-\u00a511\u5104\", \"ebit\": -1135000000.0, \"ebit_fmt\": \"-\u00a511\u5104\", \"net_income\": -1112000000.0, \"net_income_fmt\": \"-\u00a511\u5104\", \"eps\": -6.62, \"operating_margin\": -184.6, \"total_assets\": 2229000000.0, \"total_assets_fmt\": \"\u00a522\u5104\", \"total_equity\": 1874000000.0, \"total_equity_fmt\": \"\u00a519\u5104\", \"total_debt\": 60000000.0, \"total_debt_fmt\": \"\u00a560.0M\", \"total_cash\": 728000000.0, \"total_cash_fmt\": \"\u00a57\u5104\", \"equity_ratio\": 84.07, \"de_ratio\": 0.03, \"current_ratio\": 3.33, \"operating_cf\": -359000000.0, \"operating_cf_fmt\": \"-\u00a54\u5104\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 275000000.0, \"financing_cf_fmt\": \"\u00a53\u5104\", \"free_cf\": -359000000.0, \"free_cf_fmt\": \"-\u00a54\u5104\", \"net_margin\": -180.23, \"roe\": -59.34, \"roa\": -49.89}, {\"year\": 2022, \"revenue\": 1092000000.0, \"revenue_fmt\": \"\u00a511\u5104\", \"gross_profit\": 662000000.0, \"gross_profit_fmt\": \"\u00a57\u5104\", \"operating_income\": -2471000000.0, \"operating_income_fmt\": \"-\u00a525\u5104\", \"ebit\": -2474000000.0, \"ebit_fmt\": \"-\u00a525\u5104\", \"net_income\": -2548000000.0, \"net_income_fmt\": \"-\u00a525\u5104\", \"eps\": -16.77, \"operating_margin\": -226.28, \"total_assets\": 3134000000.0, \"total_assets_fmt\": \"\u00a531\u5104\", \"total_equity\": 2662000000.0, \"total_equity_fmt\": \"\u00a527\u5104\", \"total_debt\": 37000000.0, \"total_debt_fmt\": \"\u00a537.0M\", \"total_cash\": 803000000.0, \"total_cash_fmt\": \"\u00a58\u5104\", \"equity_ratio\": 84.94, \"de_ratio\": 0.01, \"current_ratio\": 3.53, \"operating_cf\": -2074000000.0, \"operating_cf_fmt\": \"-\u00a521\u5104\", \"investing_cf\": -418000000.0, \"investing_cf_fmt\": \"-\u00a54\u5104\", \"financing_cf\": 2571000000.0, \"financing_cf_fmt\": \"\u00a526\u5104\", \"free_cf\": -2477000000.0, \"free_cf_fmt\": \"-\u00a525\u5104\", \"net_margin\": -233.33, \"roe\": -95.72, \"roa\": -81.3}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": -2473000000.0, \"operating_cf_fmt\": \"-\u00a525\u5104\", \"investing_cf\": -164000000.0, \"investing_cf_fmt\": \"-\u00a52\u5104\", \"financing_cf\": 361000000.0, \"financing_cf_fmt\": \"\u00a54\u5104\", \"free_cf\": -2636000000.0, \"free_cf_fmt\": \"-\u00a526\u5104\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-59381","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SOLASIA PHARMA K K - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4597\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4597\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4597\/\",\"name\":\"SOLASIA PHARMA K K - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:35:18+00:00\",\"dateModified\":\"2026-08-23T04:56:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4597\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4597\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4597\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOLASIA PHARMA K K\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOLASIA PHARMA K K - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4597\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4597\/","url":"https:\/\/japanir.jp\/en\/company\/company-4597\/","name":"SOLASIA PHARMA K K - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:35:18+00:00","dateModified":"2026-08-23T04:56:03+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4597\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4597\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4597\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"SOLASIA PHARMA K K"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/59381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=59381"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=59381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}